There is a risk of hyperkalaemia if angiotensin II
receptor antagonists are given with
potassium supplements or potassium-containing salt substitutes, particularly in those patients where other risk factors (such as advanced age, reduced
renal function, and type II diabetes) are present.
Monitor
potassium levels, adjusting supplementation as necessary.